Thomas E. Polen Jr.
Known title: Executive Vice PresidentCIK: 0001621793
Associated companies
Transaction History
| BDX | ▲ Buy | Option Exercise | 43,278 | $7.2M | 8/13/2026 | View on chart |
| BDX | ▼ Sell | Other | 39,126 | $7.2M | 8/13/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 4,152 | $768K | 8/13/2026 | View on chart |
| BDX | ▲ Buy | Option Exercise | 20,209 | $2.5M | 6/1/2026 | View on chart |
| BDX | ▼ Sell | Other | 17,445 | $2.5M | 6/1/2026 | View on chart |
| BDX | ▼ Sell | Open Market | 2,764 | $405K | 6/1/2026 | View on chart |
| BDX | ▲ Buy | Grant | 22,521 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 17,421 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 23,564 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 15,539 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 36,585 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 32,296 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 19,574 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Grant | 11,429 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Grant | 11,577 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Grant | 17,678 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 10,473 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Option Exercise | 15,000 | $2.5M | 8/15/2022 | View on chart |
| BDX | ▼ Sell | Other | 5,500 | $1.5M | 8/15/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 9,500 | $2.5M | 8/15/2022 | View on chart |
| BDX | ▲ Buy | Option Exercise | 3,825 | $565K | 8/9/2022 | View on chart |
| BDX | ▼ Sell | Other | 2,173 | $565K | 8/9/2022 | View on chart |
| BDX | ▼ Sell | Open Market | 1,652 | $430K | 8/9/2022 | View on chart |
| BDX | ▲ Buy | Grant | 2,786 | $0 | 11/26/2021 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,913 | $0 | 11/26/2021 | View on chart |
| BDX | ▲ Buy | Grant | 10,583 | $0 | 11/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.